Akebia Therapeutics (FRA:AX9) EV-to-Revenue : 1.48 (As of Apr. 29, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Akebia Therapeutics's enterprise value is €266.4 Mil. Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €180.4 Mil. Therefore, Akebia Therapeutics's EV-to-Revenue for today is 1.48.

The historical rank and industry rank for Akebia Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:AX9' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.35 Med: 1.33 Max: 93.5
Current: 1.47

During the past 12 years, the highest EV-to-Revenue of Akebia Therapeutics was 93.50. The lowest was -0.35. And the median was 1.33.

FRA:AX9's EV-to-Revenue is ranked better than
82.38% of 1033 companies
in the Biotechnology industry
Industry Median: 7.66 vs FRA:AX9: 1.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Akebia Therapeutics's stock price is €1.195. Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.96. Therefore, Akebia Therapeutics's PS Ratio for today is 1.24.

Akebia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Akebia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics EV-to-Revenue Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.18

0.92

1.83

0.40

1.27

Akebia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															0.40	0.48	0.88	1.16	1.27

Competitive Comparison of Akebia Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Akebia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's EV-to-Revenue falls into.

Akebia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Akebia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	266.374	/	180.443
	=	1.48

Akebia Therapeutics's current Enterprise Value is €266.4 Mil.
Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €180.4 Mil.

Akebia Therapeutics (FRA:AX9) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Akebia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.195	/	0.962
	=	1.24

Akebia Therapeutics's share price for today is €1.195.
Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.96.

Akebia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (FRA:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (FRA:AX9) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AKBA:USA

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (FRA:AX9) Headlines

No Headlines